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Immunizing pregnant women is a promising strategy to reduce infectious disease-related morbidity and
mortality in pregnant women and their infants. Important pre-requisites for the successful introduction
of new vaccines for immunization in pregnancy include political commitment and adequate financial
resources: trained, committed and sufficient numbers of healthcare workers to deliver the vaccines; close
integration of immunization programs with antenatal care and Maternal and Child Health services; ade-
quate access to antenatal care by pregnant women in the country (especially in low and middle-income
countries (LMIC)); and a high proportion of births occurring in health facilities (to ensure maternal and
neonatal follow-up can be done). The framework needed to advance a vaccine program from product
licensure to successful country-level implementation includes establishing and organizing evidence for
anticipated vaccine program impact, developing supportive policies, and translating policies into local
action. International and national coordination efforts, proactive planning from conception to implemen-
tation of the programs (including country-level policy making, planning, and implementation, regulatory
guidance, pharmacovigilance) and country-specific and cultural factors must be taken into account dur-
ing the vaccines introduction.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
2. Implementation of immunization in pregnancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32682.1. Framework for country-level implementation for a new vaccine for pregnant women. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
2.2. Supportive global vaccine policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268
2.3. Country level policy making . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
2.4. Planning and implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32693. Vaccine offered to pregnant women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269
4. Advantages of immunisation in pregnancy programs integration with antenatal care services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270
3268 S. Kochhar et al. / Vaccine 37 (2019) 3267–32775. Challenges for immunisation in pregnancy implementation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
6. Vaccine hesitancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
7. System considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32717.1. International regulatory guidance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271
7.2. Pharmacovigilance of immunisation in pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32737.2.1. Spontaneous reporting systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273
7.2.2. Active surveillance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32737.3. Ethical considerations for immunization in pregnancy programs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3274
8. Advancing of immunisation of pregnant women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3274
9. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3274
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
Conflict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
Disclaimer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32751. Introduction
Immunization in pregnancy is a promising strategy to reduce
infectious disease-related morbidity and mortality in pregnant
women and their infants [1,2]. Pregnant women and their infants
are at high risk of adverse pregnancy outcomes from infections
e.g. influenza in the last trimester can lead to severe maternal dis-
ease and rubella and zika infections in the mother can lead to con-
genital anomalies, such as congenital microcephaly.
Approximately 1.8 million children die within the first month of
life [3] with many deaths due to infections with the potential to
be prevented through existing vaccines or vaccines under develop-
ment for delivery to pregnant women. Immunization in pregnancy
protects the mother, the fetus and the newborn through the
transplacental delivery of high concentrations of protective IgG
(Immunoglobulin G) antibodies, particularly before active immu-
nization of the infant can be initiated. There is also an indirect pro-
tective effect of the immunization by preventing infection in the
mother, blocking subsequent transmission of infection to the
infants (cocooning) [4].
Vaccines against tetanus, pertussis and seasonal influenza have
been recommended for routine immunization in pregnant women
in high-income countries (HIC) and in some low and middle-
income countries (LMIC) for many years and have been determined
to be safe and effective at preventing infections [1,2,5]. In spite of
this, their uptake has been variable and for some of them e.g. influ-
enza vaccine, well below desired levels. Despite a recommendation
by WHO, influenza immunization for pregnant women has not
been incorporated into immunization programs in many LMIC.
Concerns about immunization of pregnant women include safety
of the vaccine for the mother and fetus, vaccine effectiveness in
disease prevention, limited data on the overall disease burden in
pregnant women and their infants, and the lack of concern for dis-
ease by the health care provider and the mother. New vaccines for
administration to pregnant women are currently under develop-
ment such as respiratory syncytial virus (RSV), group B streptococ-
cus (GBS), cytomegalovirus (CMV) [2,6,7] and monovalent
pertussis vaccines [8].
In 2015, the World Health Organization (WHO) Strategic Advi-
sory Group on Immunization (SAGE) reviewed progress toward
implementation of maternal influenza immunization in pregnancy
globally [9]. SAGE noted that there are still limited data from preg-
nant women, healthcare providers, and immunization program
managers to inform implementation, communications, and advo-
cacy, particularly in low resource settings.
2. Implementation of immunization in pregnancy
While awaiting the licensure of new maternal vaccines, gener-
alizable data can and should be collected from existing maternalimmunization programs regarding important pre-requisites for
their success. These include: political commitment and adequate
financial resources; trained, committed and sufficient numbers of
healthcare workers (HCW) to deliver the vaccines; close integra-
tion of antenatal care and existing maternal and child health and
immunization programs, especially in LMIC; adequate access to
antenatal care by pregnant women in the country; and a high num-
ber of pregnant women delivering in health facilities (so that
maternal, neonate and infant follow-up can be adequately done)
[10–13].2.1. Framework for country-level implementation for a new vaccine
for pregnant women
Based on the relatively recent adoption of Haemophilus influen-
zae type b (Hib), rotavirus and pneumococcal conjugate vaccines
for infants in LMIC and on an existing set of WHO guidelines for
new vaccine introduction [10], a group of vaccine authorities
developed a theoretical framework for the supportive data, poli-
cies, and activities needed to advance a vaccine program from pro-
duct licensure to successful country-level implementation (Fig. 1)
[11]. This schematic organizes the major steps in the process of
establishing and organizing evidence, developing supportive global
policies, and translating policies into local action. International and
national coordination efforts, proactive planning from conception
to implementation and country-specific, cultural and local factors
must be considered during the implementation of the immuniza-
tion in pregnancy programs [11–13]. We will use this framework
developed for implementation of infant immunizations to discuss
the specific approach to immunization in pregnancy.2.2. Supportive global vaccine policy
The WHO has recommended routine immunization of pregnant
women with tetanus, pertussis, and influenza vaccines in certain
contexts [14–16]. Other vaccines are recommended in pregnant
women with high-risk exposure during outbreaks, including
meningococcal and yellow fever vaccines [17,18]. WHO has also
produced guidance for new vaccine introduction into routine
immunization schedules [10], a global guidance document for
maternal influenza immunization implementation, as well as a
broader maternal immunization field guide for the Americas
[19,13]. WHO antenatal care guidelines also recommend strength-
ening immunization platforms during pregnancy [20]. WHO’s Glo-
bal Advisory Committee on Vaccine Safety has extensively
reviewed and published on the safety of immunization during
pregnancy. They found no evidence of adverse pregnancy out-
comes from maternal immunization with inactivated virus or bac-
terial vaccines, or toxoid [21].
Fig. 1. Schematic describing the evidence, policies, and actions required to achieve the successful implementation of a new vaccine strategy. Note: Adapted from a previously
published work [12].
Table 1
Some evidence needed by the National Immunization Technical Advisory Group
(NITAG) for the introduction of Immunization in Pregnancy vaccines.
 Disease Burden
 Epidemiology
 Vaccine Safety
 Efficacy
 Effectiveness
 Cost-effectiveness
 Quality
 Anticipated impact of the immunization program
 Vaccines risk vs benefit for each target population
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important prerequisite for new vaccine introduction. GAVI’s
financing decisions are determined by their Vaccine Investment
Strategy (VIS) recommendations, which are reviewed every
5 years. These recommendations are based on the vaccine’s impact
on health, equity and social protection, value for money, economic
impact and global health security. WHO works closely with GAVI
to determine the new vaccines that will be included in the next
VIS cycle and helps to develop the evaluation criteria based on
potential cost, vaccine impact and implementation feasibility. Feasibility and scheduling (how the vaccine would fit into the national
immunization schedule)
 Comparison of the impact of the vaccine with other interventions
 Demand forecast for the vaccine
 Regular and timely vaccine supply to meet the demand forecast
 Disease’s visibility in society and how it compares to other public health
concerns
 Implementation costs of the new vaccine for pregnant women
 Current immunization program’s performance (to identify areas that
need to be strengthened)
 Adequate infrastructure needed to monitor the disease burden and vac-
cine safety (maternal, fetal and infant adverse events)
 Regulatory and ethical considerations2.3. Country level policy making
The Expanded Programme on Immunization (EPI) managers in
countries make a preliminary, decision regarding the introduction
of new vaccines or the expanded use of existing vaccines based on
the political, financial, technical, programmatic, and feasibility
considerations. The individual country National Immunization
Technical Advisory Groups (NITAG) must support any decision
[22]. Once there is a technical consensus, the proposal can be pre-
sented to the political decision-makers [14].
According to the Global Vaccine Action Plan, endorsed by the
WHOMember States, every country has committed to having inde-
pendent NITAGs. They assist their governments in immunization
policy formation by providing evidence-based advice [22]. Small
countries in close proximity, with similar epidemiologic profiles,
and with other commonalities may participate in sub-regional
immunization technical advisory groups e.g. Caribbean Immuniza-
tion Technical Advisory Group (CITAG) (a sub-regional NITAG) for
the 22 small countries/territories in the Caribbean [23].
Each NITAG interprets available data to determine the policy
recommendations that make the most sense within the national
context. Some of the evidence that may be reviewed by the NITAGs
for the introduction of vaccines for pregnant women is listed in
Table 1 [14,24]. Existence of these data would help to assess
whether the introduction of the vaccines for pregnant women into
the national immunization program would achieve the desired
national public health objectives.Guidance for the introduction of immunization in pregnancy
programs is also available from national public health agencies
and medical societies like the American College of Obstetricians
and Gynecologists [25].
2.4. Planning and implementation
After the decision to introduce a vaccine, a plan of action for the
introduction of the new vaccines for pregnant women should be
developed. Some suggested points for consideration are included
in Table 2 [13,14].
3. Vaccine offered to pregnant women
The vaccine could be offered to the pregnant women as part of
antenatal care (ANC) visits (along with other health interventions
routinely offered in the country), outpatient care (as part of general
Table 2
Factors to consider for the introduction of new vaccines for pregnant women and the programmatic challenges for LMIC.
Factors to consider for the introduction of new vaccines for pregnant women Programmatic challenges for LMC
 Defining the target populations for the new vaccine at different levels of the
health system (national, regional, and local levels)
 Epidemiological surveillance (sentinel surveillance for high incidence dis-
eases, and national surveillance for lower incidence diseases is recommended)
 Absence of background data on disease burden and maternal and neonatal out-
comes
Difficulties in determining the denominators for vaccination coverage
 Lack of epidemiological surveillance for diseases
 Planning for the financing of the vaccine introduction  Limited resources for introduction of new vaccines and strengthening the rou-
tine immunisation programs
 Establishing vaccination strategies
 Adequate procurement mechanisms for the vaccine
 Standardization of vaccine delivery through modifications of the national vac-
cination schedule and establishment of standard
operating procedures for new vaccine introduction
 Well-functioning cold chain, waste disposal and supply chain integrated into
the national immunization program’s existing systems
 Lack of programmatically suitable vaccines to be used in low-resource settings
 Gaps in vaccine availability
 Insufficient doses of vaccines to cover all pregnant women
 Poor logistics for vaccine acquisition, storage, administration, and tracking
 Coordination among the stakeholders and regional platforms for immunisa-
tion in pregnancy (e.g. vaccine manufacturers, national regulatory bodies,
ethics committees, NITAGs, pharmacovigilance programs, maternal and child
health and immunization programs, funders, healthcare workers, scientific
communities, professional societies, non-governmental organisations (NGOs),
religious and community leaders, pregnant women, and the media)
 Consistent tools, documents (forms, reports) and information technology plat-
forms across different programs and services
 Monitoring, supervision, and evaluation for the program
 Lack of integrated approaches among stakeholders and the different programs
 Lack of promotion of maternal immunization policies by health authorities
Training for stakeholders  Lack of sufficient numbers of trained healthcare workers
 Communication plans for the public and key stakeholders
 Pharmacovigilance plans
 Crisis plans for thorough and timely response to adverse events and commu-
nication to the public and media
 Incorrect beliefs regarding immunization found in pregnant women, commu-
nities and healthcare workers (e.g. pregnant women not perceived to be at
increased risk for disease, do not believe that vaccination is a necessary pre-
ventative health measure, conspiracy theory thinking, eschewing medical pro-
viders in favor of ‘‘complementary” or ‘‘alternative” medical practices during
pregnancy, concerns about safety of vaccines for pregnant women, fetuses
and infants)
 Lack of reporting and causality assessment of adverse events
 Ineffective communication of the risks by health care workers
3270 S. Kochhar et al. / Vaccine 37 (2019) 3267–3277practice, gynecology, or high-risk clinics), vaccination on demand
and at other health services that pregnant women might seek for
their own care or for the care of their other children. Strengthening
existing maternal and neonatal initiatives such as prevention of
mother to child transmission of HIV or syphilis and incorporating
immunization of pregnant women into these initiatives would be
useful. Outreach strategies could include house-to-house vaccina-
tion, vaccination campaigns, vaccinating pregnant women at work
and educational facilities, and mobile vaccination clinics.
The timing of immunization is important, especially in LMIC
where pregnant women often access ANC initially in their second
or third trimesters. This also avoids concerns of effects on fetal
development or association mistakenly with fetal loss (which is
common in the first trimester). Placental transport is most effective
from approximately 34 weeks of gestation and higher levels of
maternal antibodies are available for transportation to the fetus,
resulting in optimal protection of the newborn infant. The first dose
of the routine immunization is started early in the neonatal period
in LMIC, hence the transplacental antibodies are required to persist
for a relatively short duration to protect the infant. For example, for
Tetanus Toxoid (TT) vaccines in India, if the immunization status of
the pregnant woman is unknown, the recommendation is immu-
nization as soon as the pregnancy is detected followed by a second
dose after 4 weeks. If the woman received two doses of TT in her
previous pregnancy within 3 years, then one dose of TT is recom-
mended 4 weeks prior to the expected date of delivery.
Vaccination coverage in pregnant women could be used as an
indicator for the integration of immunization in pregnancy with
ANC services. Latin American countries have successfully imple-
mented these health policies [14,26].4. Advantages of immunisation in pregnancy programs
integration with antenatal care services
Immunization in pregnancy could provide additional benefits
beyond the prevention of infectious diseases in the mother and
infant. Health systems for antenatal care delivery, in general,
could benefit from efforts to strengthen vaccine delivery, with
increased attention to evidence-based policy-making, regulation,
staffing, training, documentation, cold chain, supply chain, moni-
toring and evaluation of coverage, adverse event assessment, and
quality of care metrics [27]. It would potentially improve cover-
age, reduce costs, and increase the efficiency of both the antenatal
care and immunization programs [14]. Pregnant women and their
families can also benefit if vaccine introduction encourages
increased antenatal care attendance, counselling, and recom-
mended screening and interventions during pregnancy [28,29].
Systemic factors that are important to improve ANC utilization
in LMIC include the quality and satisfaction associated with the
service. Provision of immunization might help to improve both
these factors and encourage ANC uptake. Further, accompanying
family members could also receive catch-up immunization or
care during these interactions if the services for them were avail-
able at the health centers [30]. This would decrease the time that
families must invest in traveling to health facilities and the eco-
nomic costs to the families and society. However, for these inte-
grated efforts to be successful, health system strengthening is
critical. This is currently often not the case in some HIC and LMIC,
especially in smaller health care clinics in these countries, as
there currently are different days for ANC and childhood
immunizations.
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While safe and effective vaccines and global policies recom-
mending their use are necessary for the success of a new vaccine
program, they are not sufficient. Nowhere is this observation more
relevant than with the maternal influenza immunization strategy.
Influenza vaccines have an excellent safety profile in pregnant
women [31], have been shown to prevent maternal influenza
[32], and have been documented to confer protection against influ-
enza in infants [33]. However, although pregnant women are rec-
ommended to be prioritized for influenza vaccine receipt by the
WHO, only 42 percent of WHO Member States have adopted rec-
ommendations for immunization of pregnant women with influ-
enza vaccines, mostly in the American Region [34]. The coverage
of influenza immunization of pregnant women in the United States
is less than 50 percent despite recommendations for many years
from the Centers for Disease Control and Prevention (CDC), Advi-
sory Committee on Immunization Practices (ACIP) and the Ameri-
can College of Obstetricians and Gynecologists (ACOG) [25].
Maternal influenza immunization has not been adopted by most
LMIC. Reasons for not having a national maternal influenza vacci-
nation policy are multifactorial and differ among countries. Coun-
tries with policies tend to be HIC, use more new vaccines, have
more robust NITAGs to formulate vaccine policy recommendations,
and have stronger health systems to administer vaccines [34].
In the case of maternal influenza immunization, key data gaps
and challenges remain. Expert reviews of the strategy have identi-
fied lack of robust estimates for severe influenza disease in moth-
ers or their infants as a major obstacle to the strategy [33,35].
Effective mechanisms for the purchase and procurement of influ-
enza vaccines are also critical for successful immunization pro-
grams [36].
To implement an immunization in pregnancy program for a
new vaccine, programmatic challenges exist in using the antenatal
care platform to immunize pregnant women. The capacity of ante-Table 3
Some barriers that impact Healthcare Workers (HCW) provision of vaccines during
pregnancy and measures to address them.
Barriers
 Lack of knowledge and education
 Misconceptions about the risk of the disease
 Concerns about the need for vaccination during pregnancy and vaccine
safety and efficacy
 Lack of training on the technical and communication aspects
 Vaccination not being part of their routine practice
 Misconceptions regarding their patients preference for vaccination doing
pregnancy
 Lack of time, staff, vaccines, syringes, needles, cold chain equipment
 Increased workload
 Inadequate reimbursement
 Concern about liability
 Inconsistent guidelines
 Inability to track vaccination status of pregnant women
Measures to address the barriers
 Chart reminders
 Documentation in pregnancy records
 Medical notes and perinatal guidelines
 Education tailored to the needs of physicians (including family physicians
and obstetricians),
HCW and Pregnant Women (including peer to peer training/ mentoring)
 Comprehensive guidelines
 Computer decision supporting algorithms that aid in identifying women
needing immunization
 Standing and opt-in orders for vaccination
 Addressing liability issues
 Avoiding the administration of vaccines during the first trimester
 Information technology support for timely monitoring of program suc-
cesses, challenges and
impact of adding Immunisation in Pregnancy to the existing Programs
 Single-dose vaccination schedulesnatal care to deliver vaccines is LMIC is poorly characterized, how-
ever in these settings antenatal care is likely to be in need of
strengthening. WHO has recommended that pregnant women
should have at least 8 antenatal visits [37] and has highlighted
the need to improve the quality and monitoring of antenatal care.
Only about 42 percent of women from LMIC have at least four
antenatal care visits, and 35 percent still only have one antenatal
care visit [38,39]. Robust antenatal care involves the delivery of
many evidence-based interventions across several visits [40]. A
review of the quality of antenatal care found the coverage of
important evidence-based interventions to be suboptimal in many
LMIC [41].
Some of the factors which add further to the complexity of the
introduction of new vaccines for pregnant women are mentioned
in Table 2 [42,43,2,14]. Integrated approaches would need to be
supported by the availability of adequate numbers and trained
HCW, financial resources, logistics of vaccine acquisition, storage,
administration, and tracking, and consistent tools and documents
across different programs and services [44]. It is unknown how
integrated service delivery can affect the smooth operations of
health care delivery. On the one hand, it may decrease the time
and the economic costs to the families and society, but on the other
hand, it may possibly increase HCW’s daily burden of work andmay
require additional training, resources and support. Some of the bar-
riers that affect HCW provision of vaccines during pregnancy and
measures to address the issues are listed in Table 3 [1,14,45–47].6. Vaccine hesitancy
Vaccine hesitancy is the refusal of vaccines or a delay in accep-
tance despite the availability of immunization services. It is often
cited as a problem that can be particularly acute during pregnancy,
as pregnant women are encouraged to avoid medicines with
known or uncertain risks to the fetus. Some of the factors influenc-
ing vaccine hesitancy and the measures to address it in pregnant
women, their partners, and extended families are mentioned in
Table 4 [1,14,43,46–48].
Lower uptake of vaccination in pregnancy has been associated
with younger age, not being married, lacking healthcare insurance
or an obstetric care provider, having a history of pre-term delivery,
belonging to a lower socioeconomic status, having a lower educa-
tional level, and being a racial or ethnic minority [1,14,43,46–48].
To address this issue, communication, advocacy, and social
mobilization are useful to increase awareness among key stake-
holders about the importance of immunization of pregnant
women, adhering to the vaccination schedule, the safety and effec-
tiveness of the vaccines, avoiding miscommunication and rumors,
improving immunization coverage and rapid detection, reporting
and addressing of possible adverse events (AE) following immu-
nizations (AEFIs). Research from HIC and LMIC has shown that
understanding the benefits of immunization by pregnant women
(and especially in LMIC, their partners, and extended families)
comes through education by HCW, and high-quality obstetric care
with acceptable and affordable immunization services offered
through well-staffed clinics, pharmacies, churches, and other set-
tings. Recent studies support the development of interventions to
promote vaccine uptake which are evidence-based and highlight
vaccine safety during pregnancy to reduce these concerns [2,49].7. System considerations
7.1. International regulatory guidance
National Regulatory Authorities in LMIC often refer to interna-
tional guidelines from the Food and Drug Administration (FDA)
Table 4
Some factors influencing Vaccine Hesitancy in pregnant women and measures to address barriers.
Factors influencing Vaccine Hesitancy
 Perceptions about the risk of the disease and disease severity
 Lack of recommendations by healthcare workers (HCW), government, and advisorybodies
 Lack of knowledge about vaccines during pregnancy
 Mistrust of vaccines
 Concerns about vaccine safety and effectiveness
 Fear of needles
 Lack of vaccines being offered by HCW, access to vaccination services, availability of vaccines and low ANC participation
 Payment required for the vaccine and administration costs
 Lack of effective communication and dissemination of recommendations from HCW, and public health bodies
 Societal factors like family influence, social norms, religion and lack of decision-making autonomy/ skills among pregnant women
Measures to address barriers
 Education by HCW (including nurses, midwives and doctors)
 Strong healthcare worker recommendations for vaccination, including verbal, face-to–face recommendations from a physician
 Risk communication developed in collaboration with key stakeholders
 Targeting specific groups in the community e.g. women’s-groups, community and religious leaders
 Positive media coverage
 High-quality obstetric care
 Acceptable and affordable immunization services offered through well-staffed clinics (including ANC clinics, community health centers, health posts, private health
facilities, and hospitals), pharmacies, churches/ faith-based organizations, and other settings.
 Immunization services readily accessible by transportation, with convenient timings, and absence of long queues
 Reminders and follow-up (including automated text message reminders about vaccination)
3272 S. Kochhar et al. / Vaccine 37 (2019) 3267–3277and European Medicines Agency (EMA). Available guidance from
the FDA and EMA and International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) highlight a lack of harmonization and safety
monitoring expectations for immunization in pregnancy [2,50].
These vaccines present significant regulatory challenges because
their safety and efficacy must be determined both in the mother
and infant. In the ICH and FDA guidelines, general guidance is
available and specific requirements are now emerging, with the
inclusion of available data in the vaccine label on immunization
of pregnant women [2,51].
In the United States, no vaccine currently has an approved label
for an indication for use during pregnancy. This is due to a lack of
evidence from controlled clinical trials in pregnant women at the
time of initial licensure of the vaccine, on the safety of the vaccine
in the vaccinated woman and infant and the effectiveness of the
vaccine to protect the infant. This is needed to include an indica-
tion for use in pregnant women in the vaccine label. Pregnant
women were excluded from most pre-licensure trials for licensed
vaccines in HIC. Public health authorities have recommended the
same vaccine for immunization in pregnancy based on reproduc-
tive toxicity studies in the preclinical phase, post-licensure surveil-
lance, observational studies, data from small numbers of pregnant
women inadvertently vaccinated in vaccination campaigns and
clinical trials, and the vaccine’s perceived benefit and minimal risk
for the mother and infant [2,51,52]. Currently, vaccines recom-
mended by the ACIP (e.g. Tetanus, Diphtheria and Pertussis (Tdap),
and inactivated influenza) can be used in pregnant women, as they
are approved for use in adults and not contraindicated for use dur-
ing pregnancy [2,51–53].
Differences between the public health recommendations
regarding the vaccine use in pregnant women and the absence of
the indication on the vaccine label can lead to confusion in HCW
and pregnant women and result in lower compliance with
national vaccination recommendations [54]. The language in the
vaccine inserts may be misinterpreted to suggest safety concerns
[2,51,53]. To address the potential for misinterpretation of -
pregnancy-related language in vaccine inserts, the FDA issued the
Pregnancy and Lactation Labeling Rule (PLLR) to improve under-
standing of vaccine risks [2,50,52,55]. The PLLR eliminates the ear-
lier letter categories (A, B, C, D, X) meant to signify risk, which were
difficult to practically implement [2,54].The revised PLLR regulation requires narrative descriptions of
clinically relevant information on the risks of using the vaccine
in pregnant and lactating women to be included in the label. The
data can come from clinical trials, epidemiologic studies, preg-
nancy registries, and case series reporting rare events. As new
information becomes available, the vaccine label needs to be
updated. This may help towards informing HCW’s prescriptions
for immunization, counselling pregnant women and communicat-
ing information on the benefits and risks of the vaccine use in preg-
nancy and lactation and in males and females with reproductive
potential [2,52,55,56].
In 2015, the Vaccines and Related Biological Products Advisory
Committee of the FDA determined that the regulatory approval
process for vaccines for use in pregnant women to prevent disease
in the infant will be guided by regulations in Title 21 of the Code of
Federal Regulations (21 CFR) and standards mentioned in applica-
ble guidance documents i.e. the ICH and FDA Guidance documents.
The vaccine development program and licensure will be product-
specific to support the particular indication. Key considerations
could include the use of immunological endpoints as markers of
infant protection, evaluation of immune interference of transpla-
centally derived antibody with childhood vaccines and the dura-
tion of immunity in both the vaccinated woman and infant.
Observational studies could be used for the study of licensed vac-
cines already recommended for use during pregnancy [2,54].
Using standardized case definitions for maternal and neonatal
outcomes will enable the pooling of data from clinical and observa-
tional studies for the vaccine labels [2]. Having clarity regarding
vaccine labeling related to pregnancy will help reduce variability
in the labels and ensure that health care providers and pregnant
women have a higher level of confidence in vaccines to be admin-
istered in pregnancy. This will hopefully increase the uptake of
immunization in pregnancy [2,52,53]. Well-defined international
guidance could provide a roadmap for regulation of vaccines used
during pregnancy in LMIC.
For new RSV and GBS vaccines under development, advance
agreement on the design and parameters of clinical trials that
could support licensure for immunization in pregnancy by regula-
tory authorities in countries will be useful. Important work done
by WHO to define the technological roadmap and preferred pro-
duct characteristics for the RSV and GBS vaccines has been accom-
plished [57,58]. Another area of importance will be to agree on
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follow-up to gather further safety and efficacy information from
the field if investigational candidate vaccines are deployed in LMIC
that currently do not have systems for such surveillance in place.7.2. Pharmacovigilance of immunisation in pregnancy
Monitoring the safety of vaccines in the woman and infant
should be an important part of any immunization in pregnancy
program. HIC have developed vaccine safety monitoring systems
that have been used to monitor the safety of vaccines for pregnant
women [59–63]. Unlike HIC, LMIC face challenges in their efforts to
monitor the safety of immunization in pregnancy. Some limita-
tions encountered by LMIC include lack of background population
data on important pregnancy or infant outcomes necessary for
immunization in pregnancy safety surveillance [2,64]. Prematurity,
small for gestational age, and pregnancy complications are not
uncommon in pregnancies, even in the absence of vaccination.
The baseline rates of adverse pregnancy outcomes in a population
should be enumerated to understand expected baselines of AE to
inform vaccine safety assessments and clinically important effect
sizes, if there were safety signals that must be captured by safety
monitoring systems [2,65].
Adverse events following immunization (AEFI) surveillance
should be established to identify AE if they were to occur. This is
to ensure that the risk–benefit balance remains positive in preg-
nant women and their newborns [66]. Vaccine pharmacovigilance
includes three stages: signal detection, development of a causality
hypothesis, and testing of the hypothesis [67].7.2.1. Spontaneous reporting systems
Signal detection in the post-marketing setting mainly relies on
spontaneous reports of AEFI and literature case reports (passive
pharmacovigilance) [67].
Many LMIC have spontaneous reporting systems with different
degrees of pharmacovigilance [68]. There are national spontaneous
reporting databases that collaborate with the WHO Programme for
International Drug Monitoring. The Global Individual Case Safety
Reports Database System (VigiBase) is a WHO global database
which contains over 16 million individual case safety reports with
member countries of the WHO Programme for International Drug
Monitoring submitting reports since 1968. VigiBase is linked to
medical and drug classifications such as WHO ART (Adverse Reac-
tions Terminology), MedDRA (Medical Dictionary for Regulatory
Activities), WHO ICD (International Classification of Diseases),
and WHODrug to enable structured data entry, retrieval and anal-
ysis [69]. Analyses of spontaneous reports may provide a signal for
higher than expected AE rates or potentially previously unrecog-
nized AE. However, there are many limitations to the evaluation
of passive reports including extremely low reporting of AEFIs by
healthcare providers [2,66], selective reporting of AE, lack of
denominator data, incomplete data on AE, lack of evidence sup-
porting the diagnosis submitted in many reports and the lack of
control groups [70].
AEFI causal relationships can usually not be determined based
on individual reports [71]. Determining if there is a causal relation-
ship between vaccination in early pregnancy and birth defects
would require a statistically significant difference in the group of
pregnant women receiving the vaccines compared to a control
group. This is often limited by an inadequate sample size/power
to detect differences. A false positive finding, where an association
between the vaccine and outcome is incorrectly identified can
potentially affect public trust in vaccination and/or the rates of
vaccine coverage [2,72,73].7.2.2. Active surveillance
Signals coming from spontaneous reports warrant additional
epidemiological and clinical investigations and further confirma-
tion in a controlled study may be required [73]. Pharmaco-
epidemiological studies using large electronic health record
databases make it possible to study the association of rare AE
and provide timely answers to meet the short deadlines of the
pharmacovigilance decision-making process. This not only simpli-
fies the logistics and reduces the costs of pharmaco-
epidemiological research, but can also increase it validity [74].
However, these electronic databases contain observational data
which has not been collected for research purposes. Vaccine safety
studies that use these databases are limited by the quality of the
information. As a result, biased results due to potential misclassifi-
cation of the exposure (vaccination) and/or outcome (AE) are pos-
sible [75]. The combined use of multiple healthcare databases for
the conduct of post-marketing active surveillance studies for vac-
cine safety is being increasingly done especially in HIC to increase
the statistical sample size and heterogeneity of exposure. There are
issues associated with this approach, including the different under-
lying healthcare systems, type of information collected, lack of har-
monized case definitions, medical event coding systems, language
and programs selected for data management and analyses. These
large databases also need to respect country-specific data
anonymization and privacy regulations. Specific software (e.g. Jer-
boa) deal with privacy issues by using a common data model and
sharing only aggregated and anonymized data. Providing remote
research environments for storage and safe access to the data from
different databases is necessary [76].
Several HIC have developed active surveillance systems for AEFI
for analyses of the association between a vaccine and one or more
pre-specified adverse health outcomes e.g. CDC’s Vaccine Safety
Datalink (VSD), the US FDA’s Post-Licensure Rapid Immunization
Safety Monitoring (PRISM) and IMPACT, Canada’s Immunization
Monitoring program. Rapid Cycle Analysis (RCA) (frequent (e.g.,
weekly) analysis) of the VSD allows more timely analysis of pre-
specified AE of special interest so the general public can be
informed rapidly of possible risks of recently licensed vaccines or
new immunization schedules. TreeScan (https://www.treescan.
org/), a free analytical software for large datasets, can be used to
identify previously unspecified outcomes by simultaneously evalu-
ating thousands of groups of AE and potential AE, to determine if
there is a higher probability of any adverse event occurring among
people exposed to a particular vaccine [77].
Some LMIC have surveillance and survey systems in place that
have been established to collect population health data including
maternal health data e.g. health and demographic surveillance sys-
tems (HDSS). However, such databases might contain aggregated
data making analysis impossible at the individual level. House-
holds are visited regularly and this could serve as a platform to col-
lect data on the safety of immunization in pregnancy. Pregnancy
registries may be set up and used to collect immunization in preg-
nancy safety data, but their use in LMIC has been limited. Health
information systems (HIS) can collect data on subjects who attend
health facilities; however, they can lack standardized definitions
and be biased. One potential approach for safety monitoring of
maternal vaccines in LMIC is the use of a network of hospitals or
health centers within a country or in several countries using
case-only analytic methods to circumvent the difficulty of obtain-
ing denominator data to calculate rates of AE. An example of this is
monitoring conducted by the Pediatric Investigators Collaborative
Network on Infections (PICNIC) in Canada for RSV-associated
deaths in pediatric patients [78]. A similar approach could be used
to study the safety of vaccines for pregnant women as was done to
assess the safety of the pandemic H1N1 influenza vaccine in preg-
nant women in Taiwan [79]. Landscape analysis could be used to
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of vaccines administered to pregnant women.
The Latin American Center for Perinatology (CLAP) was estab-
lished in 1970 with the aim of strengthening health care services
especially primary care for mothers and neonates. In recent years,
CLAP has compiled data from 29 countries in Latin America using
an electronic, standardized perinatology clinical record. This tool
has helped with the analyses of health outcomes of interest for
Maternal and Neonatal Immunisation. CLAP is also establishing a
surveillance network of sentinel hospital sites across the Region.
These sentinel centers will actively look for and investigate preg-
nancy and infant outcomes following immunization in pregnancy
[80].
A limitation, not unique to LMIC but also present in some HIC, is
the lack of harmonized methods for vaccine safety studies, lack of
standard definitions for important pregnancy and infant outcomes
such as fetal loss, stillbirth, birth defects, and maternal morbidity
and causality assessment for maternal or fetal AEFI in pregnancy
[2,64,81]. This is being addressed through the Global Alignment
of Immunization safety Assessment in pregnancy (GAIA) project,
which was set up in 2014 in response to theWHO call for a globally
concerted approach to actively monitor the safety of vaccines and
immunization in pregnancy programs, with a specific focus on
LMIC needs and requirements [2,64]. The project has developed a
core set of 25 globally standardized case definitions of selected
key obstetric and neonatal outcomes to determine the level of
diagnostic certainty in the assessment of an event to ensure com-
parability and harmonization of data collected in different resource
settings [81,82]. In addition, guidelines and tools for assessment of
the safety of vaccines used in clinical trials in pregnant women
have been developed. The guidelines have been supported by
WHO Global Advisory Committee on Vaccine Safety [2,64,82,83].
The GAIA outputs have been developed based on a standard global
consensus process with investigators, academia, vaccine manufac-
turers and public health institutes. They are being increasingly uti-
lized in the field of immunization in pregnancy and maternal and
child health [2,64].
The surveillance of vaccine safety in pregnant women in LMIC is
especially challenging. The small differences in risk that would be
expected need big sample sizes to perform studies with adequate
statistical power. To date, most published studies on vaccine safety
in pregnancy have been from HIC [68]. This may be explained in
part by the lack of appropriate databases in LMIC. The strengthen-
ing, adaptation, and use of the expanding information sources are
the next step to generate complementary information for the con-
tinuous benefit-risk assessment process.
7.3. Ethical considerations for immunization in pregnancy programs
The principle of fair distribution of research benefits requires
that research addresses diverse health needs across different
classes/groups of people and not disproportionately focus on the
health needs of a limited class of people. In the past, groups consid-
ered vulnerable have had additional protections to participate in
research, often including investigations designed to exclude them
(e.g. women of reproductive age, pregnant women, children etc.)
[84–86]. Due to the exclusions, information about the prevention,
diagnosis, and treatment of diseases that affect such groups is lim-
ited. This has resulted in injustice to pregnant women from a jus-
tice, equity, medical need, ethical and public health perspective
[2,84–87]. Pregnant women were denied autonomy and a right
to decide on research participation for themselves.83Not vaccinat-
ing pregnant women deprives them of the protection they deserve
against infectious diseases [84–87]. The International Ethical
Guidelines for Health-related Research Involving Humans by the
Council for International Organizations of Medical Sciences(CIOMS), in collaboration with WHO, note that pregnant women
are not vulnerable simply because they are pregnant [84]. There
is a need to redress these injustices by encouraging the participa-
tion of previously excluded groups, including pregnant women,
in medical research and offering immunization to pregnant women
if the vaccines have been licensed or recommended for use in preg-
nancy in those countries [2,84–87].
Based on the principle of autonomy, in no case must the permis-
sion of another person replace the requirement of individual
informed consent by the pregnant woman to receive the vaccine.
In case the pregnant women so desires, the information about
the vaccines can be shared with her spouse and extended family
[85,86]. Providing easily understandable, culturally sensitive, com-
prehensive information in the locally spoken language on the ben-
efits and risks of immunization in pregnancy is important, so
that pregnant women can make their own decision to get immu-
nized [2,84–87].
Active dialogue between pregnant women and HCW in the com-
munity is necessary to understand pregnant women’s beliefs about
the necessity and safety of immunization in pregnancy. Taking the
perspectives of women seriously contributes to the ethical justifica-
tion and trustworthiness of the program. Women should also be
adequately represented in decision-making bodies that influence
national- and international-level policy decisions about immuniza-
tion in pregnancy programs (including the NITAG, community advi-
sory groups, policymakers, scientific bodies’ etc.) [2,84–87].8. Advancing of immunisation of pregnant women
Robust disease burden and cost-effectiveness estimates for RSV
and GBS are being collected and will serve to inform expectations
of vaccine program impact [6,7]. These vaccines are also being
developed with WHO programmatic suitability criteria in mind,
so clinical development will consider issues of product storage vol-
ume, cold chain, injection devices, and waste disposal that are of
particular concern in LMIC [88]. GBS and RSV vaccines have several
advantages over influenza vaccines, as they will not require annual
reformulation; they will likely have longer shelf lives, and will not
require frequent stock rotations [6,7]. However, the kinetics of the
antibody responses to these vaccines will need to be characterized
[6,7]. Maternal antibodies generally wane over a period of less than
6 months. If there are higher titers of maternal antibody present in
the neonate after birth, they will persist for a longer time in the
infant. Immunizing pregnant women during the late second or
third trimester (after 20 weeks and, preferably at 27–36 weeks of
gestation) is recommended [89,90].
There is reason to be optimistic about the implementation of
immunization in pregnancy for a number of maternal and neonatal
pathogens. Using GBS as an example, it will be far easier to admin-
ister a vaccine than to culture clinical specimens from every preg-
nant woman for GBS carriage and then treat each colonized women
with antibiotics to prevent a single case of early-onset GBS disease
[91]. Routinely collecting clinical specimens for culture from preg-
nant women for GBS is not done in LMIC. Even with the develop-
ment of highly specific and sensitive rapid bedside GBS
diagnostic tests, their use would likely not be possible in LMIC
due to logistic and financial considerations. In addition, the cultur-
ing and treatment approach has no effect on the prevention of late-
onset GBS meningitis in the infant, as shown by the existing data
from the United States [92].9. Conclusion
An investment in an immunization in pregnancy strategy would
provide public health benefit by preventing infectious diseases in
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antenatal care and health care delivery systems. To implement
an immunization in pregnancy program for a new vaccine, pro-
grammatic challenges exist in using the antenatal care platform
to deliver vaccines, especially in LMIC. These are mentioned in
Table 2. Based on the lessons learned from current immunization
in pregnancy programs, if the introduction of new vaccines for
pregnant women is systemically done this may considerably
decrease the morbidity and mortality associated with vaccine-
preventable infectious diseases in pregnant women and their
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